Quest Diagnostics (DGX) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Revvity (RVTY) has outperformed Quest Diagnostics (DGX) over the past year, gaining 68.9% versus a gain of 25.3%. Over five years, DGX leads with a +59.9% price change compared with -9.3% for RVTY. Quest Diagnostics is the larger company by market cap ($25.06 billion vs $17.14 billion), about 1.5 times the size.
On valuation, Quest Diagnostics trades at a lower forward P/E (18.8x vs 26.1x for Revvity). Quest Diagnostics offers the higher dividend yield (1.46% vs 0.18%). Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DGX | RVTY |
|---|---|---|
| Share price | $227.06 | $153.60 |
| Market cap | $25.06B | $17.14B |
| 1-day change | -0.58% | +0.20% |
| YTD return | +31.33% | +59.21% |
| 1-year return | +25.30% | +68.92% |
| 5-year return | +59.93% | -9.29% |
| P/E ratio (TTM) | 24.10 | 73.49 |
| Forward P/E | 18.83 | 26.07 |
| EPS (TTM) | $9.42 | $2.09 |
| Dividend yield | 1.46% | 0.18% |
| Annual dividend | $3.32 | $0.28 |
| Revenue (latest FY) | $11.04B | $2.86B |
| Revenue growth (YoY) | +11.78% | +3.67% |
| Net income (latest FY) | $992.00M | $241.20M |
| Gross margin | 33.21% | — |
| Operating margin | 14.10% | 12.49% |
| Net margin | 8.99% | 8.45% |
| 52-week high | $248.84 | $166.25 |
| 52-week low | $171.18 | $81.22 |
| Distance from 52-week high | -8.75% | -7.61% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.25% | -11.54% |
| Average volume | 1.04M | 1.77M |
| Shares outstanding | 110.37M | 111.59M |
| Employees | 46,000 | 11,000 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVTY has outperformed DGX by 43.6 percentage points over the past year.
- Revvity trades at a higher earnings multiple (73.5x vs 24.1x trailing P/E).
- Quest Diagnostics offers a meaningfully higher dividend yield (1.46% vs 0.18%).
- Quest Diagnostics grew revenue faster in its latest fiscal year (+11.78% vs +3.67%).
About Quest Diagnostics
DGX stock →Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Healthcare · Diagnostics & Research · 46,000 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Healthcare · Diagnostics & Research · 11,000 employees
DGX vs RVTY FAQ
Which is bigger, Quest Diagnostics or Revvity?
Quest Diagnostics (DGX) is larger, with a market capitalization of $25.06B compared with $17.14B for Revvity (RVTY).
Which stock has performed better over the past year, DGX or RVTY?
RVTY returned +68.92% over the past 12 months, compared with +25.30% for DGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DGX or RVTY?
DGX has the lower trailing P/E at 24.1, versus 73.5 for RVTY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Quest Diagnostics or Revvity?
Quest Diagnostics has the higher yield at 1.46%, compared with 0.18% for Revvity.
Are Quest Diagnostics and Revvity in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.